RT Journal Article
SR Electronic
T1 Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20152967
DO 10.1101/2020.07.15.20152967
A1 Thomas M Drake
A1 Annemarie B Docherty
A1 Ewen M Harrison
A1 Jennifer K Quint
A1 Huzaifa Adamali
A1 Sarah Agnew
A1 Suresh Babu
A1 Christopher M Barber
A1 Shaney Barratt
A1 Elisabeth Bendstrup
A1 Stephen Bianchi
A1 Diego Castillo Villegas
A1 Nazia Chaudhuri
A1 Felix Chua
A1 Robina Coker
A1 William Chang
A1 Anjali Crawshaw
A1 Louise E. Crowley
A1 Davinder Dosanjh
A1 Christine A Fiddler
A1 Ian A. Forrest
A1 Peter George
A1 Michael A Gibbons
A1 Katherine Groom
A1 Sarah Haney
A1 Simon P Hart
A1 Emily Heiden
A1 Michael Henry
A1 Ling-Pei Ho
A1 Rachel K Hoyles
A1 John Hutchinson
A1 Killian Hurley
A1 Mark Jones
A1 Steve Jones
A1 Maria Kokosi
A1 Michael Kreuter
A1 Laura MacKay
A1 Siva Mahendran
A1 George Margaritopoulos
A1 Maria Molina-Molina
A1 Philip L Molyneaux
A1 Aiden O’Brien
A1 Katherine O’Reilly
A1 Alice Packham
A1 Helen Parfrey
A1 Venerino Poletti
A1 Joanna Porter
A1 Elisabetta Renzoni
A1 Pilar Rivera-Ortega
A1 Anne-Marie Russell
A1 Gauri Saini
A1 Lisa G Spencer
A1 Giulia M. Stella
A1 Helen Stone
A1 Sharon Sturney
A1 David Thickett
A1 Muhunthan Thillai
A1 Tim Wallis
A1 Katie Ward
A1 Athol U Wells
A1 Alex West
A1 Melissa Wickremasinghe
A1 Felix Woodhead
A1 Glenn Hearson
A1 Lucy Howard
A1 J Kenneth Baillie
A1 Peter J.M. Openshaw
A1 Malcolm G Semple
A1 Iain Stewart
A1 ISARIC4C Investigators
A1 R Gisli Jenkins
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.15.20152967.abstract
AB Rationale The impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established.Objectives To assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched population.Methods An international multicentre audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death.Measurements and Main Results Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and comorbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC ≥80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 1.98, 1.13−3.46).Conclusions Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.Competing Interest StatementDr. Jenkins reports grants from Astra Zeneca, grants from Biogen, personal fees from Boehringer Ingelheim, personal fees from Daewoong, personal fees from Galapagos, grants from Galecto, grants from GlaxoSmithKline, personal fees from Heptares, non-financial support from NuMedii, grants and personal fees from Pliant, personal fees from Promedior, non-financial support from Redx, personal fees from Roche, other from Action for Pulmonary Fibrosis, outside the submitted work. Dr. Russell reports personal fees from Hoffman La Roche, grants from NIHR BRC, during the conduct of the study. Dr. MOLINA-MOLINA reports personal fees from Esteve-Teijin, grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, outside the submitted work. Dr. Bendstrup reports grants, personal fees and non-financial support from Boehringer Ingelheim, grants, personal fees and non-financial support from Hoffmann la Roche, outside the submitted work. Prof. Semple reports grants from DHSC National Institute of Health Research UK, grants from Medical Research Council UK, grants from Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool, during the conduct of the study; other from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. Dr. Wells reports personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche Pharmaceuticals, personal fees from Blade. Dr. George reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche Pharmaceuticals, personal fees from Teva, outside the submitted work.outside the submitted work. Dr. Castillo reports personal fees and non-financial support from Roche, personal fees and non-financial support from Boehringer-Ingelheim, grants from Fujirebio, outside the submitted work.Funding StatementRGJ is supported by an NIHR Research Professor Award (RP-2017-08-ST2-014). LPH is supported by the NIHR Oxford Biomedical Research Centre. This work is supported by grants from: the National Institute for Health Research [award CO-CIN-01], the Medical Research Council [grant MC_PC_19059] and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [NIHR award 200907], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre for providing infrastructure support for this research (Grant Reference: C18616/A25153). The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics and Consent Only data that were obtained as part of routine clinical care were collected and entered into the ILD Audit. All data were de-identified and entered by the Local Clinical Care Team in anonymised fashion without linkage to any patient identifiers in line with national and local guidance. In the UK Health Research Authority guidance was followed (https://www.hra.nhs.uk/covid-19-research/guidance-using-patient-data/), and therefore consent and ethical approval was not required. Data for control patients was obtained from the ISARIC4C CCP-UK study, which received ethical approval from the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149), and by the Scotland A Research Ethics Committee (Ref: 20/SS/0028). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified, anonymised, and unlinked data from the ILD Audit can be shared on request. ISARIC 4C data can be accessed in line with data sharing policy https://isaric4c.net